Enhancement of Antitumor Immunity by CTLA-4 Blockade

These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells

Dana R. Leach; Matthew F. Krummel; James P. Allison

2006

Key concepts

Scholarcy highlights

  • One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells
  • It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation
  • In vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors
  • This rejection resulted in immunity to a secondary exposure to tumor cells
  • These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells

Need more features? Save interactive summary cards to your Scholarcy Library.